MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma

被引:9
作者
Du, Wei [1 ]
Chen, Dayu [1 ]
Wei, Ke [1 ]
Yu, Duo [1 ]
Gan, Zhiqiang [1 ]
Xu, Guozheng [1 ]
Yao, Guojie [1 ]
机构
[1] Gen Hosp Cent Theater Command, Dept Neurosurg, 627 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China
关键词
glioblastoma; immune evasion; miR-10b-5p; PD-L1; TET2; TET2; GROWTH;
D O I
10.1620/tjem.2023.J028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glioblastoma (GBM) is a highly aggressive primary brain tumor that shows intratumoral heterogeneity at the cellular and molecular level. Activation of programmed death receptor 1 (PD-1) interaction with its ligand PD-L1 is a well-known mechanism requisite for immune evasion deployed by malignant tumors including GBM. Herein, we set out to dissect the mechanism explaining the regulation of PD-L1 gene expression in GBM. The clinical samples consisted of 37 GBM tissues and 18 normal brain tissues. GBM cell model was treated by microRNA (miRNA) inhibitor, DNA constructs, and siRNAs. Assays of CCK-8 and Transwell insert were employed to assess the survival, migratory and invasive ability of GBM cell model. The immunosuppressive factor production, T cell apoptosis, and T cell cytotoxicity to GBM cells were evaluated in the co-culture system. GBM exhibited more miR-10b-5p abundance than normal at both tissue and cellular level. Suppression of miR-10b-5p weakened the ability of GBM cell model to survive, migrate, and invade, decreased the release of immunosuppressive factors, reduced T cell apoptosis, and strengthened the T cell cytotoxicity to GBM cell model. MiR-10b-5p conferred a negative control of Ten-eleven translocation 2 (TET2) that was downregulated in GBM. The functions of miR-10b-5p on GBM cell aggressiveness and immune evasion were mediated by TET2. TET2 recruited histone deacetylases HDAC1 and HDAC2 into the PD-L1 promoter region thus inhibiting its transcription. The study demonstrated the importance of miR-10b-5p-mediated repression of TET2 in PD-L1-driven immune evasion and their potential for immunotherapeutic targeting in GBM.
引用
收藏
页码:205 / 214
页数:10
相关论文
共 36 条
[1]   TET proteins regulate T cell and iNKT cell lineage specification in a TET2 catalytic dependent manner [J].
Aijo, Tarmo ;
Theofilatos, Dimitris ;
Cheng, Meng ;
Smith, Matthew D. ;
Xiong, Yue ;
Baldwin, Albert S. ;
Tsagaratou, Ageliki .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[2]   Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy [J].
Ananta, Jeyarama S. ;
Paulmurugan, Ramasamy ;
Massoud, Tara F. .
MOLECULAR PHARMACEUTICS, 2016, 13 (09) :3164-3175
[3]   The Profiles of Tet-Mediated DNA Hydroxymethylation in Human Gliomas [J].
Bragiel-Pieczonka, Aneta ;
Lipka, Gabriela ;
Stapinska-Syniec, Angelika ;
Czyzewski, Michal ;
Zybura-Broda, Katarzyna ;
Sobstyl, Michal ;
Rylski, Marcin ;
Grabiec, Marta .
FRONTIERS IN ONCOLOGY, 2022, 12
[4]   Next Steps for Immunotherapy in Glioblastoma [J].
Cao, Toni Q. ;
Wainwright, Derek A. ;
Lee-Chang, Catalina ;
Miska, Jason ;
Sonabend, Adam M. ;
Heimberger, Amy B. ;
Lukas, Rimas, V .
CANCERS, 2022, 14 (16)
[5]   Repression of the expression of TET2 by ZEB1 contributes to invasion and growth in glioma cells [J].
Chen, Bo ;
Lei, Yanqing ;
Wang, Hongquan ;
Dang, Yanwei ;
Fang, Peihai ;
Wang, Jun ;
Yang, Jinbo ;
Liu, Lijun .
MOLECULAR MEDICINE REPORTS, 2017, 15 (05) :2625-2632
[6]   DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages [J].
Cobo, Isidoro ;
Tanaka, Tiffany N. ;
Mangalhara, Kailash Chandra ;
Lana, Addison ;
Yeang, Calvin ;
Han, Claudia ;
Schlachetzki, Johannes ;
Challcombe, Jean ;
Fixsen, Bethany R. ;
Sakai, Mashito ;
Li, Rick Z. ;
Fields, Hannah ;
Mokry, Michal ;
Tsai, Randy G. ;
Bejar, Rafael ;
Prange, Koen ;
de Winther, Menno ;
Shadel, Gerald S. ;
Glass, Christopher K. .
IMMUNITY, 2022, 55 (08) :1386-+
[7]   Obstacles to Glioblastoma Treatment Two Decades after Temozolomide [J].
Cruz, Joao Victor Roza ;
Batista, Carolina ;
Afonso, Bernardo de Holanda ;
Alexandre-Moreira, Magna Suzana ;
Dubois, Luiz Gustavo ;
Pontes, Bruno ;
Moura Neto, Vivaldo ;
Mendes, Fabio de Almeida .
CANCERS, 2022, 14 (13)
[8]   PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer [J].
Diskin, Brian ;
Adam, Salma ;
Cassini, Marcelo F. ;
Sanchez, Gustavo ;
Liria, Miguel ;
Aykut, Berk ;
Buttar, Chandan ;
Li, Eric ;
Sundberg, Belen ;
Salas, Ruben D. ;
Chen, Ruonan ;
Wang, Junjie ;
Kim, Mirhee ;
Farooq, Mohammad Saad ;
Nguy, Susanna ;
Fedele, Carmine ;
Tang, Kwan Ho ;
Chen, Ting ;
Wang, Wei ;
Hundeyin, Mautin ;
Rossi, Juan A. Kochen ;
Kurz, Emma ;
Ul Haq, Muhammad Israr ;
Karlen, Jason ;
Kruger, Emma ;
Sekendiz, Zennur ;
Wu, Dongling ;
Shadaloey, Sorin A. A. ;
Baptiste, Gillian ;
Werba, Gregor ;
Selvaraj, Shanmugapriya ;
Loomis, Cynthia ;
Wong, Kwok-Kin ;
Leinwand, Joshua ;
Miller, George .
NATURE IMMUNOLOGY, 2020, 21 (04) :442-+
[9]   Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b [J].
El Fatimy, Rachid ;
Subramanian, Shruthi ;
Uhlmann, Erik J. ;
Krichevsky, Anna M. .
MOLECULAR THERAPY, 2017, 25 (02) :368-378
[10]   Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy [J].
Fekrirad, Zahra ;
Barzegar Behrooz, Amir ;
Ghaemi, Shokoofeh ;
Khosrojerdi, Arezou ;
Zarepour, Atefeh ;
Zarrabi, Ali ;
Arefian, Ehsan ;
Ghavami, Saeid .
CANCERS, 2022, 14 (15)